Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)
Others
Ratios

CASI Pharmaceuticals (CASI) Research & Development (2022 - 2025)

Historic Research & Development for Pharmaceuticals (CASI) over the last 4 years, with Q2 2025 value amounting to -$1.7 million.

  • Pharmaceuticals' Research & Development fell 3748.01% to -$1.7 million in Q2 2025 from the same period last year, while for Jun 2025 it was -$7.4 million, marking a year-over-year increase of 6056.35%. This contributed to the annual value of -$8.9 million for FY2024, which is 957.31% up from last year.
  • As of Q2 2025, Pharmaceuticals' Research & Development stood at -$1.7 million, which was down 3748.01% from -$1.9 million recorded in Q1 2025.
  • Pharmaceuticals' Research & Development's 5-year high stood at $4.0 million during Q1 2022, with a 5-year trough of -$27.7 million in Q4 2022.
  • For the 4-year period, Pharmaceuticals' Research & Development averaged around -$2.8 million, with its median value being $572500.0 (2023).
  • In the last 5 years, Pharmaceuticals' Research & Development soared by 3725.49% in 2023 and then crashed by 19771.11% in 2024.
  • Over the past 4 years, Pharmaceuticals' Research & Development (Quarter) stood at -$27.7 million in 2022, then surged by 37.25% to -$17.4 million in 2023, then surged by 92.8% to -$1.3 million in 2024, then tumbled by 37.48% to -$1.7 million in 2025.
  • Its last three reported values are -$1.7 million in Q2 2025, -$1.9 million for Q1 2025, and -$1.3 million during Q2 2024.